Tigecycline: First of a New Class of Antimicrobial Agents
- 1 August 2006
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 26 (8), 1099-1110
- https://doi.org/10.1592/phco.26.8.1099
Abstract
Tigecycline is the first commercially available member of the glycylcyclines, a new class of antimicrobial agents. The glycylcyclines are derivatives of the tetracycline antibiotics, with structural modifications that allow for potent gram-positive, gram-negative, and anaerobic activity, including certain multidrug-resistant strains. The enhanced activity can be attributed to stronger binding affinity and enhanced protection against several mechanisms of resistance that affect other antibiotic classes such as tetracyclines. Tigecycline exhibits generally bacteriostatic action by reversibly binding to the 30S ribosomal subunit and inhibiting protein translation. In vitro activity has been demonstrated against multidrug-resistant gram-positive pathogens including methicillin-resistant and glycopeptide-intermediate and -resistant Staphylococcus aureus, as well as vancomycin-resistant enterococci. Multidrug-resistant gram-negative pathogens, such as Acinetobacter baumannii and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli, are typically highly susceptible to tigecycline. The drug also has displayed significant activity against many clinically important anaerobic organisms. This agent demonstrates a predictable pharmacokinetic profile and minimal drug interactions, and is generally well tolerated, with nausea being the most common adverse event. It was approved in June 2005 for the treatment of complicated skin and skin structure infections (SSSIs) and complicated intraabdominal infections. Currently, a limited number of broad-spectrum antimicrobials are available to combat multidrug-resistant organisms. The addition of new agents is essential to limiting the spread of these pathogens and improving outcomes in patients with these types of infections. Tigecycline has demonstrated promising results in initial in vitro and clinical studies for SSSIs and complicated intraabdominal infections; however, further clinical experience will clarify its role as a broad-spectrum agent.Keywords
This publication has 53 references indexed in Scilit:
- In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)Diagnostic Microbiology and Infectious Disease, 2005
- In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)Journal of Antimicrobial Chemotherapy, 2005
- Staphylococcus aureus with Reduced Susceptibility to VancomycinClinical Infectious Diseases, 2004
- Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNAJournal of Antimicrobial Chemotherapy, 2004
- Vancomycin-Resistant Staphylococcus aureus Isolate from a Patient in PennsylvaniaAntimicrobial Agents and Chemotherapy, 2004
- In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamasesDiagnostic Microbiology and Infectious Disease, 2001
- Preclinical Pharmacology of GAR-936, a Novel Glycylcycline Antibacterial AgentPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
- In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive BacteriaAntimicrobial Agents and Chemotherapy, 2000
- Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936Bioorganic & Medicinal Chemistry Letters, 1999
- Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibilityJournal of Antimicrobial Chemotherapy, 1997